State Responses to High Cost Therapies: Using Research to Inform Policy

SAN FRANCISCO, MARCH 3, 2015

Mark Gibson

Center for Evidence-based Policy Oregon Health & Science University



FUNDING

- Milbank Memorial Fund
- State health care programs
- CMS
- Primary care transformation projects with commercial payer participation



OUTLINE

- State health policy context
- Description of general approaches
- Multi-state Collaborations
- Application of research to policy
- State response to HCV



STATE HEALTH POLICY CONTEXT

- Limited resources for health spending
 - Balanced budget requirements
 - Competing priorities
 - Education
 - Employee benefits
 - Corrections
 - Environment
- Advocates & industry pushing for more
- Anti-tax activists pushing for tighter limits



GENERAL APPROACHES USED BY STATES

- Laissez-faire FFS (non-accountable care)
- Loosely overseen managed care
- Self-managed care or carefully watched commercial managed care
- Benefit design and coverage decisions
 - Contract and politics
 - Using research to push value and inform decisions



USING RESEARCH TO INFORM POLICY AND DRIVE VALUE

- Multi-state collaborations
 - DERP and MED
- Variety of approaches for applying research
 - Washington HTA
 - Oregon HERC
 - NY
 - Strong Medicaid Medical Director



STATE RESPONSE TO HCV

| POLICY CRITERIA | | NUMBER OF STATES |
|--|------------------------------------|------------------|
| No apparent restrictions on coverage | | 7 |
| Once in a lifetime benefit? | | 6 |
| Disease severity requirement? | | 22 |
| | ≥ F4 | 4 |
| | ≥ F3 | 15 |
| | ≥ F2 | 2 |
| | Level unclear | 1 |
| Response driven therapy | | 9 |
| Require providers to collect SVR 12 & SVR 24 | | 3 |
| SUD criteria | | 22 |
| | ≥ 3 months sober | 3 |
| | ≥ 6 months sober | 13 |
| | ≥ 12 months sober | 2 |
| | During treatment, or not specified | 4 |
| Specialist physician requirement | Prescribe | 10 |
| | Prescribe or consult | 9 |
| Could not identify policy online | | 15 |

COMING SOON TO A PROGRAM NEAR YOU

- Cross sector backlash to Pharma pricing (including generics)
- Increasing interest in social determinates of health
- More sophisticated and strategic view of budget effects
- Social Impact Bonding to bridge funding gap between applying social interventions and health returns



Oh you can't always get what you want, but if you try sometimes, you just might find, you get what you need.

Jagger, M. & Richards, K.

Mark Gibson

Director

Center for Evidence-based Policy
Oregon Health & Science University

gibsomar@ohsu.edu (503) 494-2679

